GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (FRA:AYJ) » Definitions » EV-to-FCF

Valneva SE (FRA:AYJ) EV-to-FCF : -2.58 (As of May. 05, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Valneva SE EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Valneva SE's Enterprise Value is €560.6 Mil. Valneva SE's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-217.1 Mil. Therefore, Valneva SE's EV-to-FCF for today is -2.58.

The historical rank and industry rank for Valneva SE's EV-to-FCF or its related term are showing as below:

FRA:AYJ' s EV-to-FCF Range Over the Past 10 Years
Min: -31429.13   Med: -3.14   Max: 185.38
Current: -2.58

During the past 13 years, the highest EV-to-FCF of Valneva SE was 185.38. The lowest was -31429.13. And the median was -3.14.

FRA:AYJ's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 4.57 vs FRA:AYJ: -2.58

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Valneva SE's stock price is €3.498. Valneva SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.730. Therefore, Valneva SE's PE Ratio for today is At Loss.


Valneva SE EV-to-FCF Historical Data

The historical data trend for Valneva SE's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE EV-to-FCF Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -47.46 5.11 -143.95 -2.65 -3.40

Valneva SE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.65 -2.12 -3.77 -3.81 -3.40

Competitive Comparison of Valneva SE's EV-to-FCF

For the Biotechnology subindustry, Valneva SE's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Valneva SE's EV-to-FCF falls into.



Valneva SE EV-to-FCF Calculation

Valneva SE's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=560.587/-217.056
=-2.58

Valneva SE's current Enterprise Value is €560.6 Mil.
Valneva SE's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-217.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valneva SE  (FRA:AYJ) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Valneva SE's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.498/-0.730
=At Loss

Valneva SE's share price for today is €3.498.
Valneva SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.730.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Valneva SE EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Valneva SE's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE (FRA:AYJ) Business Description

Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.

Valneva SE (FRA:AYJ) Headlines

No Headlines